Epi-Pen

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) wants to stop egregious drug pricing issues, and Mallinckrodt PLC (NYSE: MNK) is its next target. Imprimis announced it will pursue a lower priced alternative to Mallinckrodt's HP Acthar Gel, which grossed sales of $1.3 billion in the prior year....